Charles Russell Speechlys advises on sale of Silver Cross
Charles Russell Speechlys has advised the shareholders of Silver Cross, the heritage British high-end baby brand founded in 1877 and famous for its coach-built baby prams, on a sale of the company to Fosun International, China’s leading investment group.
Alan Halsall acquired the business in 2002 and has sold his entire shareholding. A management team comprising Nick Paxton, and members of the Halsall family, Jonathan Halsall and Ben Halsall will remain as investors in the new business as they seek to grow operations around the world.
Alan Halsall said: “I was delighted with the work done by Charles Russell Speechlys, who not only supported me but also ensured the existing management at Silver Cross were kept up to speed throughout the deal. The team was extremely professional at all times but also very smart in ensuring the transaction went through smoothly by recognising the important issues on which to focus. ”
Andrew Collins, Corporate Partner at Charles Russell Speechlys, said: “We are delighted to have advised the shareholders of such an iconic British brand on the sale to Fosun. The transaction represents a significant milestone for Alan Halsall in exiting the business and also for the management team who can look forward to exciting times ahead. ”
The Charles Russell Speechlys team was led by Corporate Partner Andrew Collins, with Senior Associate David Coates and Associate Sarah Aldersley, as well as specialists from the Corporate Tax, Real Estate, Employment and Private Wealth teams.
The firm’s ability to draw on a multidisciplinary team, offering business and personal advice, ensured that advice was in line with personal objectives.
The shareholders of Silver Cross were also advised by Cavendish Corporate Finance (Jonathan Buxton and Fiona McCormick). Fosun was advised by Clifford Chance (Gareth Camp and Grace Yuen).
News & Insights
Charles Russell Speechlys advises Emergex Vaccines on $11m fundraising
Emergex is a UK-based biotechnology company and pioneers of developing synthetic ‘set point’ vaccines .
Public Company Update - November 2020
The November 2020 edition of our biannual Public Company Update.